At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Total Lymphoid Irradiation, Thymoglobulin, and Rituximab for Allogeneic Transplantation in Lymphoid Malignancies
In Brief
A clinical study evaluating Thymoglobulin, Total Lymphoid Irradiation, and 2 other interventions for Lymphoma and Leukemia. Completed, enrolled 20 participants across 1 site.
Detailed Summary
Primary Objective: 1\. To determine whether the primary endpoint: the composite success rate, defined as the proportion of patients who are alive at day 100; and are without grade 3-4 Graft versus Host Disease (GVHD); and are without grade 4 toxicity (unrelated to infection); and have engrafted, is likely to be at least 40%. Secondary Objectives: 1. To determine the cumulative incidence of chronic graft versus host disease. 2. To determine the overall and disease free survival.
Study Details
Timeline
Interventions
1.5 mg/kg by vein on Days -11 to -7.
80 cGy daily on days -11 to -7 and -4 to 0.
PBSC infusion administered on day 0.
375 mg/m\^2 by vein on days -13, -6, 1, \& 8. Only those patients whose tumors express CD20 will receive Rituximab.